Literature DB >> 11448727

Antisense oligonucleotides in cutaneous therapy.

C J Wraight1, P J White.   

Abstract

Antisense oligonucleotides have been the subject of intense interest as research tools to elucidate the functions of gene products and as therapeutic agents. Initially, their mode of action was poorly understood and the biological effects of oligonucleotides were often misinterpreted. However, research into these gene-based inhibitors of cellular action recently has succeeded in realising their exciting potential, particularly as novel therapeutic agents. An emerging application of this technology is in cutaneous therapy. The demand for more effective dermatological drugs will ensure further development of antisense strategies in skin, with key issues being drug delivery, therapeutic target selection, and clinical applicability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448727     DOI: 10.1016/s0163-7258(01)00133-4

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  4 in total

Review 1.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Spherical Nucleic Acids as Emerging Topical Therapeutics: A Focus on Psoriasis.

Authors:  Emrullah Korkmaz; Louis D Falo
Journal:  J Invest Dermatol       Date:  2020-02       Impact factor: 8.551

3.  Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis.

Authors:  Ahmet Tezel; Sujatha Dokka; Susan Kelly; Gregory E Hardee; Samir Mitragotri
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

4.  Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis.

Authors:  Jung-Yeon Kim; Hyun-Jin An; Woon-Hae Kim; Mi-Gyeong Gwon; Hyemin Gu; Yoon-Yub Park; Kwan-Kyu Park
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-03       Impact factor: 8.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.